Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review (Q34384181)

1 August 2017

0 references

Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review (English)

1 reference

1 August 2017

J Oliveira

7

0 references

Marion Leboyer

11

object named as

M Leboyer

1 reference

1 August 2017

3

F Kapczinski

1 reference

1 August 2017

G Fond

1

1 reference

1 August 2017

N Hamdani

2

1 reference

1 August 2017

W Boukouaci

4

1 reference

1 August 2017

N Drancourt

5

1 reference

1 August 2017

A Dargel

6

1 reference

1 August 2017

E Le Guen

8

1 reference

1 August 2017

E Marlinge

9

1 reference

1 August 2017

R Tamouza

10

1 reference

1 August 2017

language of work or name

English

0 references

publication date

11 November 2013

1 reference

Acta Psychiatrica Scandinavica

1 August 2017

published in

1 reference

1 August 2017

volume

129

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

163-179

1 reference

Grand challenges in global mental health

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The burden of brain diseases in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The size and burden of mental disorders and other disorders of the brain in Europe 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

From inflammation to sickness and depression: when the immune system subjugates the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

A psychoneuroimmunological review on cytokines involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

A review of the fetal brain cytokine imbalance hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Inflammation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Can bipolar disorder be viewed as a multi-system inflammatory disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Are some cases of psychosis caused by microbial agents? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Multiple sclerosis and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Bipolar disorder and resembling special psychopathological manifestations in multiple sclerosis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Antidepressant drugs and experimental inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Association of depressive disorders, depression characteristics and antidepressant medication with inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Effects of antipsychotic drugs on cytokine networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Infliximab improves quality of life in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Minocycline: therapeutic potential in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Clinical potential of minocycline for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

COX-2 inhibitors as adjunctive therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

A systematic review of the evidence for the treatment of acute depression in bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Effects of omega 3 fatty acids supplementation in behavior and non-neurodegenerative neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

(N-3) Fatty acids: molecular role and clinical uses in psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Early interventions to prevent psychosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Fish consumption and the risk of gastric cancer: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Relation between red blood cell omega-3 fatty acid index and bleeding during acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Omega-3 and fish oil supplements do not cause increased bleeding during spinal decompression surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Nonsteroidal antiinflammatory drugs--differences and similarities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-D-aspartate receptors in rat hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

NMDA-induced seizure intensity is enhanced in COX-2 deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Maternal corticosterone influences behavior, stress response and corticosteroid receptors in the female rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Habituation and cortisol dysregulation in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Celecoxib augmentation of continuously ill patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Minocycline as adjunctive therapy for schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Cause for concern in the use of non-steroidal anti-inflammatory medications in the community--a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Brain arachidonic acid uptake and turnover: implications for signaling and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Mood-stabilizers target the brain arachidonic acid cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Bipolar disorder and mechanisms of action of mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Molecular effects of lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Anterior cingulate activation and error processing during interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Update on the management of inflammatory bowel disease: specific role of adalimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

TNF-α antagonists beyond approved indications: stories of success and prospects for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Association between anti-TNF-α therapy and all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Latent viral infections in young patients with inflammatory diseases treated with biological agents: prevalence of JC virus genotype 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Pharmacokinetic studies on minocycline in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Reduced neurogenesis after suppressed inflammation by minocycline in transient cerebral ischemia in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

A novel model of continuous depletion of glutathione in mice treated with L-buthionine (S,R)-sulfoximine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Quinones and glutathione metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12211

21 January 2018

Identifiers

DOI

10.1111/ACPS.12211

1 reference

1 August 2017

1 reference